论文部分内容阅读
Ph(+)慢性粒细胞白血病(CML)慢性期的血液学变化虽易被马利兰或羟基脲控制,但无论是这些药物还是强烈化疗都不能治愈这一疾病,但现已证明骨髓移植能治愈任何病期的病人。现在的问题是应在什么时候移植。化疗的结果 Sokal等分析了625例5-45岁的CML病人后,发现年龄、脾脏大小、血小板计数、血细胞比积、外周血原始细胞比例等5项指标对预测用传统方法治疗的病人生存期有用。约2/3病人属高危组,其5年存活率为40%,活过7年者很少;1/3病人属低危组,5年存活率60%,约90%病人能活过2年,比做骨髓移植好;但第7年,只有40%存活,以后生存率继续直线下降。
Chronic hematologic changes in Ph (+) chronic myeloid leukemia (CML), which are easily controlled by either marilan or hydroxyurea, can not be cured by either these drugs or by intensive chemotherapy but it has been shown that bone marrow transplantation can cure any Illness of the patient. The question now is when to transplant. Results of Chemotherapy After analyzing 625 CML patients 5-45 years of age, Sokal et al. Found that five indicators of age, spleen size, platelet count, hematocrit, and proportion of peripheral blood blast cells in predicting the survival of patients treated with traditional methods it works. About 2/3 of the patients are in the high-risk group, whose 5-year survival rate is 40%, few survive 7 years; 1/3 patients belong to the low-risk group, 5-year survival rate of 60%, about 90% of patients survived 2 Year, better than bone marrow transplantation; but the first 7 years, only 40% of the survival, after the survival rate continued to plummet.